The death toll from prescription painkiller overdose across the U.S. has increased more than five times in the past decade (from 3,000 deaths in 1999 to 15,500 in 2009), prompting the Centers for Disease Control to define the problem as an epidemic.
Hazelden facilities have seen a corresponding increase in the number of patients seeking treatment for opioid addiction. In Center City, Minn., for example, those seeking treatment for opioid addiction rose from 19 percent of patients in 2001 to 30 percent in 2011. An even more dramatic jump was seen at Hazelden’s facility for young adults and adolescents in Plymouth, Minn., from 15 percent of patients in 2001 to 41 percent in 2011.
As part of a comprehensive response to this crisis, Hazelden offers extended, adjunctive medication assisted treatment for opioid dependence as a means to help people achieve a stable, Twelve Step-based recovery lifestyle and ultimate abstinence from opioids. Hazelden is committed to using scientific evidence to continuously improve our treatment methods and outcomes.
Our goal will be to discontinue the medications as our patients become established in long-term recovery. Hazelden will study the results of these new treatment protocols and share the results through our Butler Center for Research.
Hazelden’s mission, vision and values statements are clear in outlining our responsibility to pursue the best, most effective methods for treating our patients.